You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

Version: 2 ID: 3-15 sep 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
E. Basch, D.A. Loblaw, T.K. Oliver, C. Bennett, M. Carducci, R. Chen, J. Frame, K. Garrels, S. Hotte, M. Kattan, R. Nam, D. Raghavan, F. Saad, M.E. Taplin, C. Walker-Dilks, J. Williams, E. Winquist, T. Wooten, K. Virgo, CCO-ASCO Joint Castration Resistant Prostate Cancer Expert Panel Genitourinary Cancer Disease Site Group

Guideline Objective

To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC).

Patient Population

Men with metastatic castration-resistant prostate cancer.

Research Question(s)

In men with metastatic castration-resistant prostate cancer (mCRPC), which systemic therapies improve cancer- or patient-related outcomes?

pdf download Summary (PDF) (162.34 Ko)